JP7510943B2 - Ｐｄ－１軸指向型治療薬に対する応答を予測するための方法およびシステム - Google Patents

Ｐｄ－１軸指向型治療薬に対する応答を予測するための方法およびシステム Download PDF

Info

Publication number
JP7510943B2
JP7510943B2 JP2021542071A JP2021542071A JP7510943B2 JP 7510943 B2 JP7510943 B2 JP 7510943B2 JP 2021542071 A JP2021542071 A JP 2021542071A JP 2021542071 A JP2021542071 A JP 2021542071A JP 7510943 B2 JP7510943 B2 JP 7510943B2
Authority
JP
Japan
Prior art keywords
roi
cells
tumor
features
axis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021542071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513316A (ja
JP2022513316A5 (https=
Inventor
メルヌーシュ コーヤステ，
ジム マーティン，
リディヤ ペスティック－ドラゴヴィッチ，
レイ タン，
シャンシュー ワン，
ウェンチュン チャン，
ロバート アンダース，
ルイス ディアズ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2022513316A publication Critical patent/JP2022513316A/ja
Publication of JP2022513316A5 publication Critical patent/JP2022513316A5/ja
Priority to JP2024036619A priority Critical patent/JP7802843B2/ja
Application granted granted Critical
Publication of JP7510943B2 publication Critical patent/JP7510943B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/0002—Inspection of images, e.g. flaw detection
    • G06T7/0012—Biomedical image inspection
    • G06T7/0014—Biomedical image inspection using an image reference approach
    • G06T7/0016—Biomedical image inspection using an image reference approach involving temporal comparison
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00—ICT specially adapted for the handling or processing of medical images
    • G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00—ICT specially adapted for the handling or processing of medical images
    • G16H30/40—ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/10—Image acquisition modality
    • G06T2207/10056—Microscopic image
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/30—Subject of image; Context of image processing
    • G06T2207/30004—Biomedical image processing
    • G06T2207/30024—Cell structures in vitro; Tissue sections in vitro
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/30—Subject of image; Context of image processing
    • G06T2207/30004—Biomedical image processing
    • G06T2207/30096—Tumor; Lesion

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Databases & Information Systems (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Quality & Reliability (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Theoretical Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021542071A 2018-10-01 2019-09-30 Ｐｄ－１軸指向型治療薬に対する応答を予測するための方法およびシステム Active JP7510943B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024036619A JP7802843B2 (ja) 2018-10-01 2024-03-11 Ｐｄ－１軸指向型治療薬に対する応答を予測するための方法およびシステム

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862739828P 2018-10-01 2018-10-01
US62/739,828 2018-10-01
US201862742934P 2018-10-09 2018-10-09
US62/742,934 2018-10-09
PCT/US2019/053774 WO2020072348A1 (en) 2018-10-01 2019-09-30 Methods and systems for predicting response to pd-1 axis directed therapeutics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024036619A Division JP7802843B2 (ja) 2018-10-01 2024-03-11 Ｐｄ－１軸指向型治療薬に対する応答を予測するための方法およびシステム

Publications (3)

Publication Number Publication Date
JP2022513316A JP2022513316A (ja) 2022-02-07
JP2022513316A5 JP2022513316A5 (https=) 2022-10-11
JP7510943B2 true JP7510943B2 (ja) 2024-07-04

Family

ID=68296689

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021542071A Active JP7510943B2 (ja) 2018-10-01 2019-09-30 Ｐｄ－１軸指向型治療薬に対する応答を予測するための方法およびシステム
JP2024036619A Active JP7802843B2 (ja) 2018-10-01 2024-03-11 Ｐｄ－１軸指向型治療薬に対する応答を予測するための方法およびシステム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024036619A Active JP7802843B2 (ja) 2018-10-01 2024-03-11 Ｐｄ－１軸指向型治療薬に対する応答を予測するための方法およびシステム

Country Status (5)

Country Link
US (1) US12086985B2 (https=)
EP (1) EP3861556A1 (https=)
JP (2) JP7510943B2 (https=)
CN (1) CN112789684B (https=)
WO (1) WO2020072348A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3871183B1 (en) * 2018-10-23 2024-10-09 F. Hoffmann-La Roche AG Distance-based tissue state determination
CN110866908B (zh) * 2019-11-12 2021-03-26 腾讯科技（深圳）有限公司 图像处理方法、装置、服务器及存储介质
EP4186026A1 (en) 2020-07-21 2023-05-31 F. Hoffmann-La Roche AG Method of generating a metric to quantitatively represent an effect of a treatment
JP7629185B2 (ja) * 2020-12-25 2025-02-13 株式会社カイ 癌の再発可能性を判定する再発判定装置および再発判定方法
US20240193772A1 (en) * 2021-04-22 2024-06-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Quantifying the tumor-immune ecosystem in non-small cell lung cancer (nsclc) to identify clinical biomarkers of therapy response
AU2022288930A1 (en) * 2021-06-09 2023-12-14 The Johns Hopkins University Method of predicting response to immunotherapy
CN113933505B (zh) * 2021-12-15 2022-04-05 北京市肿瘤防治研究所 一组多维分析预测胃癌免疫治疗疗效的tiic指标及其应用
JP2025513724A (ja) 2022-03-31 2025-04-30 ヴェンタナ メディカル システムズ， インク． ミスマッチ修復が欠損した結腸直腸腫瘍におけるｐｄ－１軸指向治療薬に対する応答を予測するための方法およびシステム
JP2025526652A (ja) * 2022-08-08 2025-08-15 ヴェンタナ メディカル システムズ， インク． デジタル化された病理スライドの定量化のためのシステムおよび方法
WO2024173431A1 (en) * 2023-02-14 2024-08-22 Genentech, Inc. Nuclei-based digital pathology systems and methods
CN117218139B (zh) * 2023-09-12 2024-05-24 珠海横琴圣澳云智科技有限公司 样本细胞密度的确定方法和装置
JP7783452B1 (ja) * 2025-03-28 2025-12-09 楽天グループ株式会社 情報処理装置、情報処理方法、およびプログラム

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517115A (ja) 2013-04-17 2016-06-09 ゼネラル・エレクトリック・カンパニイ 連続的に染色した組織における、１つの細胞の分割を使用する多重化バイオマーカー定量用のシステム及び方法
WO2017085307A1 (en) 2015-11-22 2017-05-26 Ventana Medical Systems, Inc. Methods of identifying immune cells in pd-l1 positive tumor tissue
US20170285029A1 (en) 2016-04-01 2017-10-05 Agilent Technologies, Inc. Immunohistochemistry scoring methods and compositions
WO2018055014A1 (en) 2016-09-23 2018-03-29 Ventana Medical Systems, Inc. Methods and systems for scoring extracellular matrix biomarkers in tumor samples
US20180134771A1 (en) 2015-05-07 2018-05-17 Bioxcel Corporation Novel immunomodulatory therapeutic strategies targeting tumors in cancer
WO2018145023A1 (en) 2017-02-06 2018-08-09 Novartis Ag Method of predicting response to immunotherapy
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1564604A (en) 1925-06-12 1925-12-08 Chas S Hodges Water wheel
US5595707A (en) 1990-03-02 1997-01-21 Ventana Medical Systems, Inc. Automated biological reaction apparatus
US20030211630A1 (en) 1998-02-27 2003-11-13 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
JP3847559B2 (ja) 1998-02-27 2006-11-22 ベンタナ・メデイカル・システムズ・インコーポレーテツド 独立スライド加熱器を有する自動化分子病理学装置
US6582962B1 (en) 1998-02-27 2003-06-24 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
US6372937B1 (en) 1998-11-09 2002-04-16 Mark Norman Bobrow Enhanced catalyzed reporter deposition
US6670113B2 (en) 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
DK1636586T3 (da) 2003-06-24 2009-11-23 Ventana Med Syst Inc Enzymkatalyseret metaldeponering til foröget in situ-detektion af immunhistokemisker epitoper og nucleinsyresekvenser
US20050186642A1 (en) 2004-02-24 2005-08-25 Biocare Medical, Inc. Immunoassay reagents and methods of use thereof
CA2842661C (en) 2009-10-19 2016-02-23 Ventana Medical Systems, Inc. Imaging system and techniques
WO2011139978A1 (en) 2010-05-04 2011-11-10 Ventana Medical Systems, Inc. Moving meniscus rinsing and mixing in cell staining
AU2011274369A1 (en) 2010-07-02 2012-12-06 Ventana Medical Systems, Inc. Hapten conjugates for target detection
FR2988549B1 (fr) 2012-03-22 2015-06-26 Bodysens Procede, terminal et casque de communication vocale sans fil avec auto-synchronisation
WO2015049233A1 (en) 2013-10-01 2015-04-09 Ventana Medical Systems, Inc. Line-based image registration and cross-image annotation devices, systems and methods
CA2940439C (en) 2014-02-24 2024-03-19 Ventana Medical Systems, Inc. Quinone methide analog signal amplification
US20160106836A1 (en) * 2014-10-17 2016-04-21 Definiens Ag Immunotherapy Using a Logical AND Combination for Immune Response Activation
WO2016170008A1 (en) 2015-04-20 2016-10-27 Ventana Medical Systems, Inc. Inkjet deposition of reagents for histological samples
EP3371594A1 (en) * 2015-11-06 2018-09-12 Ventana Medical Systems, Inc. Representative diagnostics
KR20180091024A (ko) * 2015-12-02 2018-08-14 클리어라이트 다이어그노스틱스 엘엘씨 암의 검출 및 모니터링을 위해 종양 조직 시료를 준비하고 분석하는 방법
JP7128399B2 (ja) * 2016-04-14 2022-08-31 クリエイティブ マイクロテック インコーポレーテッド 癌治療のための治療決定におけるｐｄ－ｌ１発現の使用方法
US20180112277A1 (en) * 2016-10-26 2018-04-26 Expression Pathology, Inc. Signal directed dissection to inform cancer therapy strategy

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517115A (ja) 2013-04-17 2016-06-09 ゼネラル・エレクトリック・カンパニイ 連続的に染色した組織における、１つの細胞の分割を使用する多重化バイオマーカー定量用のシステム及び方法
US20180134771A1 (en) 2015-05-07 2018-05-17 Bioxcel Corporation Novel immunomodulatory therapeutic strategies targeting tumors in cancer
WO2017085307A1 (en) 2015-11-22 2017-05-26 Ventana Medical Systems, Inc. Methods of identifying immune cells in pd-l1 positive tumor tissue
US20170285029A1 (en) 2016-04-01 2017-10-05 Agilent Technologies, Inc. Immunohistochemistry scoring methods and compositions
WO2018055014A1 (en) 2016-09-23 2018-03-29 Ventana Medical Systems, Inc. Methods and systems for scoring extracellular matrix biomarkers in tumor samples
WO2018145023A1 (en) 2017-02-06 2018-08-09 Novartis Ag Method of predicting response to immunotherapy
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Validation of Multiplex Immunofluorescence Panels Using Multispectral Microscopy for Immune-Profiling of Formalin-Fixed and Paraffin-Embedded Human Tumor Tissues，Scientific Reports，2017年，Vol.7,13380，pp.1-11，DOI: 10.1038/s41598-017-13942-8

Also Published As

Publication number Publication date
WO2020072348A1 (en) 2020-04-09
US20210374962A1 (en) 2021-12-02
CN112789684A (zh) 2021-05-11
EP3861556A1 (en) 2021-08-11
JP7802843B2 (ja) 2026-01-20
JP2022513316A (ja) 2022-02-07
JP2024096691A (ja) 2024-07-17
US12086985B2 (en) 2024-09-10
CN112789684B (zh) 2025-05-09

Similar Documents

Publication Publication Date Title
JP7802843B2 (ja) Ｐｄ－１軸指向型治療薬に対する応答を予測するための方法およびシステム
US12154275B2 (en) Methods and systems for evaluation of immune cell infiltrate in tumor samples
JP7728817B2 (ja) ステージｉｖの結腸直腸がんにおける免疫細胞浸潤の評価のための方法及びシステム
JP2019502398A (ja) 自動ダイセクション、次世代シークエンシング、及び自動スライド染色装置を用いる、腫瘍のための予測診断ワークフロー
US20190219579A1 (en) Methods and systems for scoring extracellular matrix biomarkers in tumor samples
US12422435B2 (en) Methods and systems for evaluation of immune cell infiltrate in stage III colorectal cancer
US20230204585A1 (en) Histochemical systems and methods for evaluating egfr and egfr ligand expression in tumor samples
US20250093356A1 (en) Methods and systems for predicting response to pd-1 axis directed therapeutics in colorectal tumors with deficient mismatch repair
EP3824288A1 (en) Materials and methods for detecting fusion proteins
CN118974556A (zh) 用于预测具有缺陷性错配修复的结直肠肿瘤中对pd-1轴导向疗法的反应的方法和系统

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220930

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240604

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240624

R150 Certificate of patent or registration of utility model

Ref document number: 7510943

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150